Growth
Building a solid platform for GROWTH

THE 2017 ANNUAL REPORT OF THE SOCIETY FOR NEURO-ONCOLOGY
This Annual Report covers the SNO 2017 fiscal year, from July 1, 2016 through June 30, 2017.
DEAR MEMBERS AND COLLEAGUES,

It has been an honor and a privilege to serve as the president of SNO. It has indeed been a busy time for our Society, and I would like to acknowledge the hard work of our elected leadership, committee chairs, administrative staff and our partners whose collective efforts provide a rich educational environment for our members in North America and worldwide.

Arguably, our most labor-intensive effort relates to the planning for the Annual Meeting which this year will be held in San Francisco on November 16-19, 2017. The overall theme for this meeting will focus on the Cancer Moonshot effort. I would especially like to Albert Kim and Khalid Shah for their efforts to organize an exceptional Education Day focusing on the biology and therapy-specific mechanisms of tumor resistance, as well as Sue Bell and Robert Cavaliere for their work in assembling a varied concurrent track of programming addressing survivorship, outcome measures, and mitigation of side-effects from treatment and disease. The main meeting has been ably chaired by Manish Aghi, Vinay Puduvalli and Frank Furnari. The addition of Dr. Furnari as the basic science representative is important to ensure that a meaningful number of basic science talks are included in the presentations offered in the meeting. Pre-meeting events include the SNO/SCIDOT Joint Conference on Therapeutic Delivery to the CNS, organized by Michael Vogelbaum, and again this year we thank Maciej Mrugala for organizing the Neuro-Oncology Review Course. Our technology committee chair, Erik Sulman, deserves our collective thanks for his tireless efforts to introduce new and creative ways to deliver educational content to conference attendees.

While certainly the Annual Meeting is our flagship event, this year SNO also organized a highly successful Biennial Conference on Pediatric Neuro-Oncology Basic and Translational Research in New York in June. Mark Kieran and Daphne Haas-Kogan put together a fantastic program that led to a sell-out meeting with almost 50% more registrations than what were expected! SNO congratulates the organizers for assembling a program that clearly resonated with our pediatric colleagues, and we thank the Pediatric Brain Tumor Foundation for their on-going support of this biennial event.

As an indicator of our Society’s evolution and maturity as an organization, our new Public Policy Committee is working to address legal and regulatory issues relevant to our members. This committee, led by our Vice President, Terri Armstrong, and co-chair Jann Sarkaria, sent seven junior SNO members to participate in the “Head to the Hill” advocacy event hosted by the National Brain Tumor Society in Washington, DC, in the summer.

This September, working with representatives from Bracwell, a government relations firm, I had the opportunity to join Dr. Sarkaria on Capitol Hill to meet with congressional staffers to raise awareness of the issues and priorities of the brain tumor community and specifically to advocate against the enactment of recently proposed cuts to indirect costs for NIH funded grants. The Public Policy Committee has also established a molecular diagnostics working group to explore the development of a legislative and policy approach to improve reimbursement for molecular testing for patients with brain tumors.

Perhaps our busiest committee, the Guidelines Committee, under the leadership of Tracy Batchelor and Susan Chang, has been tackling a range of issues of interest to our members. These include, but are certainly not limited to, projects to develop neuro-oncology quality measures, support of the CBTRUS Biomarker Project, a review of the NCCN CNS Cancer Guidelines, the drafting of epilepsy guidelines, and development of a neuro-oncology patient survivorship care plan.

This is the first year that SNO has guided a neuro-oncology fellowship match. Initially suggested by Tracy Batchelor and carried forward by Scott Plotkin and John DeGroot, this important effort seeks to regulate and standardize the match of fellows to programs around the country. I am pleased to report that applications are now being accepted at 28 participating institutions for 2019/2020 neuro-oncology fellowship positions.

Jason Huse and Gelareh Zadeh continue to propel our international outreach efforts forward and this year we welcome to our Annual Meeting colleagues from Egypt, Honduras, India, Mexico, Malaysia, Nepal, Nigeria, Ukraine and Vietnam. Dr. Zadeh also coordinates SNO’s administration of the Wilkins-Barrick Course in Neuro-Oncology, and I am pleased to report that a neuro-oncology course has been confirmed to take place in Peru next year, and that applications are currently being reviewed for an additional course in Sub-Saharan Africa.

It has been a privilege to serve the members and leaders of SNO during my tenure as President. I remain in awe of their dedication and indefatigable spirt as they work for the betterment of our Society, our science and our patients.

Respectfully yours,

E.A. (Nino) Chiocca, MD PhD
One of the principle challenges resulting from our dramatic growth is the logistical management of a conference that now regularly attracts over 2400 participants and continues to grow, year over year. It has become apparent that SNO will soon outgrow even the largest hotel properties in North America, and therefore we have begun planning for a transition from a hotel-based meeting into a convention center model in the near future.

We thank our Future Sites committee members, Susan Chang, Mark Gilbert and James Perry, for the significant amount of time they have devoted to traveling to venues around North America to evaluate sites for our Annual Meeting that will accommodate our continued growth, yet will also ensure the intimate feeling that has been the hallmark of SNO meetings in the past.

In addition to the Annual Meeting which remains our primary focus, SNO also works to further neuro-oncology education through the organization of stand-alone and topical events. Chaired by Mark Kieran and Daphne Haas-Kogan, a highly successful Pediatric Neuro-Oncology Basic and Translational Research Conference was held in New York this summer. We continue to support other educational events like the SNO/SCIDOT Joint Conference on Therapeutic Delivery to the CNS, organized by Michael Vogelbaum, and the CNS Anticancer Drug Discovery and Development Conference, organized by Victor Levin. And we are honored to be working with the International Symposium on Pediatric Neuro-Oncology (ISPNO) on their upcoming conference Denver in 2018.

There is no question that our in-coming President, Patrick Wen, takes the reins of a growing, dynamic organization. The administrative office looks forward to an exciting year ahead, and to providing a range of world-class programs, publications, and services to our members in North America and around the globe.

J. Charles Haynes, JD
SNO Executive Director
A MESSAGE FROM THE SNO FOUNDATION

DEAR SOCIETY FOR NEURO-ONCOLOGY MEMBERS AND SUPPORTERS,

The SNO Foundation works with the Society’s elected leadership to financially support a wide range of educational initiatives for clinicians, basic scientists, nurses and other health care professionals whose focus is the study of central nervous system tumors in children and adults.

As part of a long-term strategic plan to invest in new meeting technology, the SNO Foundation continues to support new ways to deliver educational content and enhance the meeting experience for our members. These investments include a three-fold expansion of our e-poster displays, a live simulcast of selected content, a new “text to moderator” feature and improved digital signage. This year will see the launch of a new “e-learning” center that will contain video clips of educational content captured during our annual meeting. This new web-based resource will greatly extend the educational reach of the SNO annual meeting to professionals around the world who are unable to attend the conference in person.

In addition to investments in new technology, the support of our corporate and nonprofit partners, as well as the generosity of our members, allows the Foundation to sustain SNO’s core functions. This includes financial support for:

- The editorial offices of our official publications, Neuro-Oncology, Neuro-Oncology Practice and the World Federation of Neuro-Oncology Societies Magazine.
- Research awards and new initiatives for Young Investigators
- Travel scholarships to the Annual Meeting
- International outreach efforts

This year the Foundation was pleased to provide matching funds to a generous grant made by the Greg Wilkins-Barrick Chair in Neuro-Oncology to support the organization of neuro-oncology courses in the developing world. As noted in the pages of this report, successful courses were held in Sri Lanka and Morocco, and future courses are in the planning stages for Peru and Sub-Saharan Africa.

We are grateful to the non-profit associations and corporate donors who support the Foundation at the highest level as members of our Partner’s Advisory Council. The Council has direct access to the SNO Board of Directors and the Foundation Board on a regular basis. The 2016-2017 members of the Partner’s Advisory Council include AbbVie, American Brain Tumor Association, AstraZeneca, Brain Tumour Charity, Bristol-Myers Squibb, Genentech, the National Brain Tumor Society, Novocure, and the Sontag Foundation.

The Foundation is pleased to share that the financial position of our Society is strong, and we remain well positioned to meet the diverse needs of our growing membership in the years to come.

Very truly yours,

Mitchel S. Berger, MD
Susan M. Chang, MD
Victor A. Levin, MD
The 21st Annual Scientific Meeting of the Society for Neuro-Oncology occurred on November 17-20, 2016 in Scottsdale, Arizona. The year's meeting was one of SNO’s most well attended events with 2,166 attendees registered for the main meeting, hailing from 42 countries. The Society recognizes the tremendous amount of work that went into organizing the meeting, and thanks meeting chairs Manish Aghi and Tracy Batchelor for leading what was certainly one of our most successful events.

The meeting was preceded by two well-attended satellite events. The 2nd CNS Anticancer Drug Discovery and Development Conference, organized by Victor Levin, addressed diverse viewpoints about why new drug discovery/development focused on CNS cancers has been lacking and how to overcome disincentives for pharmaceutical/biotechnology companies to enter the brain tumor space. The Neuro-Oncology Review Course, organized once again by Maciej Mrugala in cooperation with the American Academy of Neurology, provided a fast-paced, comprehensive overview of clinical neuro-oncology.

Over 970 registrants participated in the SNO Education Day which focused on Precision Medicine – the current state and future directions for precision approaches to brain tumor clinical trials and care. A mid-morning break-out session focused on improving care thought big data, and a lively mock tumor board completed the day. Special thanks are given to the Education Day Chairs, Manmeet Ahluwalia, Jaishri Blakeley, Kristina Hardy, and Keith Ligon.

Abstract submissions for this year’s main meeting reached a new record with 1,024 total submissions up from 914 in 2015. Electronic posters offered a new and interactive way to experience meeting content. In addition to the 640 traditional posters, 219 oral presentations, and 54 e-Talks were presented. Daily video highlights, the SNO Twitter feed, and the SNO annual meeting App helped connect attendees and link to important updates. Pulitzer Prize-winning author and hematologist/oncologist, Dr. Siddhartha Mukherjee, delivered a special keynote address highlighting successes and challenges in the field.

For the first time, the 2016 World Health Organization Classification of Tumors of the Central Nervous System combines molecular and histologic parameters to define brain tumors. In two Friday morning keynote presentations, Drs. David Louis and David Ellison addressed the new classifications, and what those changes may mean for both the adult and pediatric communities. After a diverse set of lunch programs, concurrent sessions were held on Clinical Trials, Tumor Biology, Radiation Therapy and Surgery. That evening, 30 e-talks were presented in a rapid-fire format that ran concurrently with the traditional poster presentations.

After the early morning Sunrise Sessions, Saturday morning featured two keynote addresses. Joseph Costello delivered a talk entitled “The parallel lives of mutations and epimutations during tumor evolution”, which was followed by Bradley Bernstein speaking on “Epigenetic mechanisms of glioma initiation and evolution”. After the Top Scoring Abstracts, a special panel moderated by Mitchel Berger discussed the Cancer Moonshot initiative. In the afternoon, attendees were able to choose from concurrent sessions on Angiogenesis, Neuro-Imaging, Pediatrics, Stem-Cells and an update from RANO. On Saturday evening, a Cirque du Soleil style Gala was held at the Scottsdale Airpark Hangar which certainly was the social highlight of the meeting.

On Sunday, the concurrent sessions focused on Molecular Pathology, Applied Neuro-Oncology, Genetics/Epigenetics, and Cell Biology. The meeting remained well-attended to the very end. The meeting concluded with remarks by the Scientific Meeting Chairs and the announcement of awards for the best posters.
SNO 21ST ANNUAL MEETING ABSTRACT
AWARD WINNERS

ADULT CLINICAL RESEARCH
Results of the phase Ib KEYNOTE-028 multi-cohort trial of pembrolizumab monotherapy in patients with recurrent PD-L1- positive glioblastoma multiforme
David Reardon

QUALITY OF LIFE RESEARCH
Award supported by the Sontag Foundation
Mutant IDH1 promotes tumor-associated epilepsy in glioma patients
Craig Horbinski

BASIC RESEARCH PEDIATRIC
R206H ACVR1 significantly accelerates diffuse intrinsic pontine glioma pathogenesis
Christine Hoeman

ADULT BASIC RESEARCH
Award supported by the National Brain Tumor Society
Single-cell profiling of glioblastoma biopsies identifies a family of activating PDGF-receptor deletions
Soeren Mueller

TRANSITIONAL RESEARCH ADULT
Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells
Elizabeth Stoll

TRANSITIONAL RESEARCH PEDIATRIC
Modeling adult proneural and mesenchymal glioblastoma using RCAS/t-va technology
Cameron Herting

YOUNG INVESTIGATOR- CLINICAL RESEARCH
Epigenomic treatment for IDH wild-type grade III glioma, targeting dysregulation of EZH2- H3K27me3
Ohka Fumiharu

ANDREW PARSA YOUNG INVESTIGATOR-BASIC SCIENCE/TRANSATIONAL
Stimulated Raman scattering microscopy provides diagnostic intraoperative histopathologic images in brain tumor patients
Daniel Orringer

CLINICAL RESEARCH PEDIATRIC
Integrated molecular and pathological characterisation of non-brainstem paediatric high grade glioma from the HERBY phase II randomised trial
Alan Mackay

EANO TRAVEL GRANT WINNER
18FET-PET uptake dynamics serves as an additional imaging biomarker in astrocytomas with IDH1/2 mutation and NIMG-34 no LOH1p/19q
Bogdana Suchorska

David Louis received the 2016 Victor Levin Award which honors an individual with a career commitment to neuro-oncology, who has demonstrated leadership and, through scientific innovation, has made extraordinary achievements in neuro-oncology research.

Mary Lovely was honored with the 2016 SNO Public Service Award in recognition of her many contributions to the field of neuro-oncology, and her tireless efforts to improve the lives of brain tumor patients, their families and caregivers.

Margaret Wrensch received the Lifetime Achievement Award from SNO President Nino Chiocca, honoring her career long dedication to advancing neuro-oncology research and mentorship.

Guha Award recipient Michael Taylor delivered a lecture entitled: Biology of Medulloblastoma Dictates Behavior in the Clinic.
As announced in last year’s report, one of the most visible changes to *Neuro-Oncology* for 2017 has been a new print internal layout and new cover design, introduced to reflect the ever increasing quality of the Journal’s content. Even more importantly the Journal was relaunched online on the new Oxford Academic Platform: [https://academic.oup.com/neuro-oncology](https://academic.oup.com/neuro-oncology)

*Neuro-Oncology* is now available to members and other readers globally on a fully-responsive design, state of the art platform, which enables easy reading on both traditional desktops & mobile devices (smartphones and tablets) including Android and iPhone.

While the Journal looks very different in print and online, behind the scenes in the Editorial Office, the same great service to authors continues: fast peer-review of manuscripts with a mean time to first decision of about 30 days during 2017 (data as at October 31, 2017). Submissions also continue apace with an increase of 7% over the previous year.

**IMPRESSIVE QUALITY**

In 2016 we reported a record high Impact Factor for *Neuro-Oncology* of 7.371 for 2015; however, we are even more delighted to highlight continued improvement in this metric for 2016 to 7.786; this ranks the Journal at 10 of 194 in Clinical Neurology and 19 of 217 Oncology titles, an achievement of which the editorial team and the published authors can be proud.

Aside from great usage and high citation impact, *Neuro-Oncology* continues to monitor and report Altmetric scores for all articles. These scores are a measure of the amount of attention an article has received online, in social media and from news sites – thus it is more a measure of the wider impact of a journal article. Hua Lin’s 2016 article *Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells* (doi: 10.1093/neuonc/now128) remains the highest Altmetric scored article in 2017 (as last year). Altmetric has seen 36 tweets from 35 users, with an upper bound of 87,489 followers – in effect bringing this particular paper to the eyes of that many interested readers via this social media route.
Like its sister journal, *Neuro-Oncology Practice* underwent an internal and cover redesign for 2017, to ensure the article layout reflects the quality of the Journal now that it is in its fourth year. It also migrated to the new Oxford Academic platform for an improved reader experience on desktop & mobile devices, with the same fully responsive design: [http://academic.oup.com/nop](http://academic.oup.com/nop)

More importantly than these print and online redesigns, 2017 has seen the Journal cement its relationship with the European Association of Neuro-Oncology with the formal affiliation (co-ownership) coming into effect; this gives all EANO members print and online access to the Journal, in addition to the large SNO membership, and institutional readers.

Dr. Susan Chang, Director of the Division of Neuro-Oncology at UCSF, continues as Editor-in-Chief, assisted by three Executive Editors: Wolfgang Grisold, for EANO, Rakesh Jalali for ASNO and Jeffrey S. Wefel for SNO, along with an esteemed team of Associate Editors: [https://academic.oup.com/nop/pages/Editorial_Board](https://academic.oup.com/nop/pages/Editorial_Board). The editorial team is determined that *Neuro-Oncology Practice* provides a truly diverse perspective on all issues of clinical importance, as well as useful updates on how new scientific advances may affect neuro-oncology patients.

*Neuro-Oncology Practice* is a truly international journal with authors and readers from the world over – albeit with a large US contingent – reflecting the proportion of US-based research in this area. 2017 has seen particularly high usage from China and within Italy.

**Figure 1: Geographic Distribution Of Online Usage 2017**

*Neuro-Oncology Practice* remains a smaller journal than *Neuro-Oncology*, as planned during the launch discussions. As of September 2017 it had published 147 articles, reviews and/or letters, but note that usage continues to increase tremendously: see Figure 2. More than 3700 mean downloads per month have been recorded for 2017.

**New submissions to Neuro-Oncology Practice** are welcome at: [https://www.editorialmanager.com/nop/default.aspx](https://www.editorialmanager.com/nop/default.aspx)

**Figure 2: Mean downloads per month since 2014**
The fourth biennial Pediatric Neuro-Oncology Basic and Translational Research Conference took place at the iconic Westin New Yorker Hotel in New York City from June 15-16, 2017.

There was excellent participation with 453 clinicians, clinician-scientists, scientists, post-doctoral and clinical fellows, graduate students and other research students, drawing investigators from 25 countries to the event. Overall, this represented an extraordinary 50% increase in attendance over the previous meeting held in 2015 in San Diego. SNO congratulates conference co-chairs Daphne Haas-Kogan and Mark Kieran for organizing this exceptional event. SNO also gratefully acknowledges the Pediatric Brain Tumor Foundation for their lead sponsorship and their on-going support of this conference.

A Neuro-Oncology Fellowship Match program has been successfully launched that streamlines the application process for both applicants and programs. Under the direction of Scott Plotkin and John De Grote, this new program provides a uniform match timeline and standardizes base application documents. It also provides time to encourage “best fit scenarios”, and establishes separate codes of conduct for applicants and programs.

Applications are now being accepted at 28 participating institutions for 2019/2020 neuro-oncology fellowship positions, a full list of which can be found on the SNO website. Results of the first match cycle will be posted in June of 2018.

This year the Society launched a new initiative entitled “SNOCares” to address results shared from the Neuro-Oncology Burnout and Career Satisfaction survey. The survey found that neuro-oncology professionals have a higher incidence of burnout than those working in other areas of cancer. In fact, 63% of respondents to the SNO survey indicated that they experienced high burnout. Through the SNOCares initiative, SNO will incorporate various activities and tools to provide healthy ways to manage stress, which in turn can mitigate symptoms of burnout.

This new wellness initiative seeks to build awareness of burnout and the utilization of techniques to improve risk factors associated with stress to improve quality of life and productivity in various aspects of one’s life. SNO thanks Alvina Acquaye, Terri Armstrong, Barbara O’Brien, and Shlomit Yust-Katz for leading this important effort.

Thanks to the generosity of the University of Toronto, the Krembil Neuroscience Centre, and the SNO Foundation, two Wilkins-Barrick International Outreach Courses were organized in 2017. The first was held in Colombo, Sri Lanka, in January. Hosted by the Neurosurgical Association of Sri Lanka, this event was a landmark occasion as it also initiated the first neurosurgical academic sessions in Sri Lanka. The second, held in Marrakech, Morocco, was organized by the Moroccan Society of Pediatric Hematology and Oncology and provided the participants with a unique opportunity to address the challenges presented by constrained neuro-oncology resources in North Africa. Future courses are in the planning stages for Peru and Sub-Saharan Africa.
SNO MEMBERS PARTICIPATE IN 2017 HEAD TO THE HILL

In May of this year, SNO sponsored nine members and staff to attend the National Brain Tumor Society’s (NBTS) annual Head to Hill advocacy event held in Washington, D.C. The SNO delegation joined nearly 300 participants, representing 38 states, who converged on Capitol Hill for meetings with their respective congressional offices to garner their support for legislative action impacting the brain tumor community.

The two-day event started with a full day of advocacy training to prepare the diverse group of brain tumor patients, survivors, caregivers, and medical doctors on how to best convey their message. On the second day, attendees readied themselves with comfortable walking shoes and donned matching “Head to Hill 2017” t-shirts to embark on a full day of congressional meetings with legislative staffers in House and Senate offices.

SNO thanks the NBTS for including SNO in this important effort. We look forward to working together on future Head to the Hill events.

SNO MOURNS THE PASSING OF JAN ESENWEIN

There was a tremendous loss to the neuro-oncology family this year with the sudden passing of Jan Esenwein. Jan had served as the Chief Administrative Officer of the Society for Neuro-Oncology since its inception in 1995.

Jan was a devoted servant of the Society, and played a vital role in helping to create the dynamic organization that SNO is today. Active even before SNO was incorporated as a non-profit, she was considered to be the matriarch of the Society. She personally folded and sealed the first membership notices, and for many years the main SNO telephone rang in her living room. She knew most members by name and took a genuine and fond interest in their work and activities. In recognition of her many years of devoted service to the Society, she was awarded with the SNO Public Service Award during the SNO Annual Meeting in 2015. Throughout her career, she supported the vision and efforts of the Society’s founders, helping the organization to rise to a level of participation and activity that few would have predicted over 20 years ago.

In recognition of Jan’s extraordinary contribution to the field of neuro-oncology, the leadership of SNO has decided to name the Public Service award in her honor, which will henceforth be known as the Jan Esenwein Public Service Award in Neuro-Oncology.

Six Young Investigator members represented SNO at the National Brain Tumor Society’s 2017 Head to the Hill event, including: Daniel O’Connell, Dima Hamideh, Surabhi Ranjan, Monica Venere, Nicole Lieberman, Jooyeon Nam. Also participating was SNO Board Member, Jeffrey Wefel, and SNO staff members, Chas Haynes and Carolyn Loch.

Janis Lynn (Piwetz) Esenwein
November 10, 1949 — March 30, 2017
The following financial highlights are prepared by management of Society for NeuroOncology for the fiscal year ended June 30, 2016 and are intended for this Annual Report, only. The financial information is in the process of being audited by an independent accounting firm. Once the audit is complete, the financial statements and Independent Auditor’s Report will be posted at www.Soc-Neuro-Onc.org.

**FINANCIAL HIGHLIGHTS**  
**FISCAL YEAR ENDED JUNE 30, 2016**

The following financial highlights are prepared by management of Society for NeuroOncology for the fiscal year ended June 30, 2016 and are intended for this Annual Report, only. The financial information is in the process of being audited by an independent accounting firm. Once the audit is complete, the financial statements and Independent Auditor’s Report will be posted at www.Soc-Neuro-Onc.org.

**STATEMENT OF FINANCIAL POSITION HIGHLIGHTS, AS OF JUNE 30, 2016:**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,288,000</td>
</tr>
<tr>
<td>Investments</td>
<td>$2,251,000</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>$298,000</td>
</tr>
<tr>
<td>Endowment assets</td>
<td>$204,000</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>$4,041,000</strong></td>
</tr>
<tr>
<td>Liabilities</td>
<td>$407,000</td>
</tr>
<tr>
<td>Net Assets</td>
<td>3,634,000</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES &amp; NET ASSETS</strong></td>
<td><strong>$4,041,000</strong></td>
</tr>
</tbody>
</table>

**STATEMENT OF ACTIVITIES HIGHLIGHTS, FOR THE FISCAL YEAR ENDED JUNE 30, 2016:**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues and other support</td>
<td>$3,515,000</td>
</tr>
<tr>
<td>Total program and supporting service expenses</td>
<td>$2,800,000</td>
</tr>
<tr>
<td><strong>CHANGE IN NET ASSETS</strong></td>
<td><strong>$715,000</strong></td>
</tr>
</tbody>
</table>
The following financial highlights are prepared by management of Society for NeuroOncology for the fiscal year ended June 30, 2017 and are intended for this Annual Report, only. The financial information is in the process of being audited by an independent accounting firm. Once the audit is complete, the financial statements and Independent Auditor’s Report will be posted at www.Soc-Neuro-Onc.org.

**FINANCIAL HIGHLIGHTS**

**FISCAL YEAR ENDED JUNE 30, 2017**

**STATEMENT OF FINANCIAL POSITION HIGHLIGHTS, AS OF JUNE 30, 2017:**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,549,000</td>
</tr>
<tr>
<td>Investments</td>
<td>$2,493,000</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>$257,000</td>
</tr>
<tr>
<td>Endowment assets</td>
<td>$242,000</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>$4,541,000</strong></td>
</tr>
<tr>
<td>Liabilities</td>
<td>$214,000</td>
</tr>
<tr>
<td>Net Assets</td>
<td>4,327,000</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES &amp; NET ASSETS</strong></td>
<td><strong>$4,541,000</strong></td>
</tr>
</tbody>
</table>

**STATEMENT OF ACTIVITIES HIGHLIGHTS, FOR THE FISCAL YEAR ENDED JUNE 30, 2017:**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Total revenues and other support</td>
<td>$3,776,000</td>
</tr>
<tr>
<td>Total program and supporting service expenses</td>
<td>$3,083,000</td>
</tr>
<tr>
<td><strong>CHANGE IN NET ASSETS</strong></td>
<td><strong>$693,000</strong></td>
</tr>
</tbody>
</table>
SNO STANDING COMMITTEES

The Audit Committee shall consist of the Chair, Vice President of the Society and the Secretary-Treasurer. The committee shall have the responsibility of overseeing annual internal audit of the Society's financial affairs, and conveying the audit to the President and the Board, who may approve review of the audit by external committees as needed. The committee shall also advise and make recommendations to the Board of Directors based on findings of such audits. The Audit Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Gene Barnett

The Awards Committee shall consist of the Chair, the Scientific Program Chair and other members who shall develop criteria for all SNO meeting awards, annually review meeting award candidates, and forward to the Board a list of awards and award recipients to be honored at the Annual Meeting. The Awards Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Tracy Batchelor

The Bylaws Committee shall consist of the Chair, the Secretary/Treasurer (ex officio) and two other members who shall review the Bylaws annually and make recommendations for revision as necessary. Members of this committee shall review any proposed changes and advise the Board of Directors on proposed revisions. The Bylaws Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: David Schiff

The Communications Committee shall consist of the Chair, the Secretary/Treasurer (ex officio) and other members who shall be responsible for the news section of the Society’s official journal and the Society’s newsletter, and will have the responsibility of advising the Board of Directors on the Society’s internal and external communications. The Communications Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Chair: Albert Kim

The Fellowship Match Committee is responsible for developing and applying codes of conduct for fellowship programs, developing and applying codes of conduct for residents, developing match participation agreements, and other actions as necessary to ensure the operations of an effective fellowship matching program. The Fellowship Match Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Co-Chairs: John de Groot, Scott Plotkin

The Future Sites Committee shall consist of the Chair, a previous Chair of the Annual Meeting Committee and two other members who shall review potential sites and hotel proposals for future meetings, evaluating size and appropriateness of meeting space, availability and quality of sleeping rooms, proposed room rates, and recommends to the Board the most appropriate venue. The Future Sites Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Co-Chairs: Susan Chang, Mark Gilbert, James Perry

The Guidelines and Reported Outcomes Committee shall be responsible for the evaluation of internally and externally produced clinical practice guidelines of potential relevance to neuro-oncology practice and will be charged with recommending approval or revisions before consideration by the Board.

Co-Chairs: Tracy Batchelor, Susan Chang

The International Outreach Committee shall consist of the Chair and other representative international members recommended by the Chair or President, as approved by the Board of Directors. The committee shall have the responsibility of advising and making recommendations to the Board of Directors on international affairs, promoting international membership, and shall develop the criteria and review candidates for SNO international outreach travel grants and fellowships. The International Outreach Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

Co-Chairs: Jason Huse, Gelareh Zadeh
The Annual Meeting Committee shall consist of a Scientific Program Chair, Education Day Chair, the immediate past Chairs of the Annual Meeting Committee and other members representing each of the SNO specialty areas who shall supervise and coordinate all aspects of the next SNO Scientific Meeting and Education Day. The Meeting Committee members shall serve a one-year term and such term may be renewable at the discretion of the President.

- **Scientific Program Chairs:** Manish Aghi, Frank Furnari, Vinay Puduvalli. Education Day Co-Chairs: Susan Bell, Robert Cavaliere, Albert Kim, Khalid Shah.

The Membership Committee shall consist of the Chair and four members who shall make recommendations to the Board of Directors concerning efforts to promote and increase membership in Society. They shall also review and vote on all applicants for membership and shall evaluate a member’s professional conduct as requested by a majority of the Board of Directors. The Membership Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

- **Chair:** Gavin Dunn

The Public Policy Committee shall advise the Board of Directors on legislative, regulatory and advocacy issues that may impact or be of interest to the SNO membership. The committee will evaluate and recommend official position statements and act as a conduit for enquiries of a public policy nature from external constituencies. It will focus on public policy issues and may be approached with opportunities to provide input related to funding or ethical issues.

- **Co-Chairs:** Terri Armstrong, Jann Sarkaria

The Technology Committee shall consist of the Chair and other members who shall have the responsibility of coordinating and overseeing the Society’s official website. The Technology Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

- **Chair:** Erik Sulman

The Young Investigators Committee shall consist of the Chair and other members who shall have the responsibility of advising the Board of Directors on issues pertaining to graduate students, residents, fellows and members within the first five years of their initial clinical or academic appointment. The Young Investigators Committee shall also have the responsibility of coordinating the SNO Grant Review initiative. The Young Investigators Committee members shall serve a two-year term and such term may be renewable at the discretion of the President.

- **Chair:** Monica Venere
Executive Director
J. Charles Haynes, JD

Manager of Medical Education
Carolyn Loch, RN

Manager, Member & Program Services
Linda Greer

Marketing and Exhibits Specialist
Megan Bell

Administrative Coordinator
Ginger Vazquez

Communications Coordinator
Kristin Odom

Bookkeeper
Martha Maloch

Society for Neuro-Oncology
PO Box 273296
Houston, TX 77277
tel 713.526.0269
fax 832.201.8129

www.soc-neuro-onc.org
SNO SUPPORTERS
THROUGH 2017 FISCAL YEAR ENDING 6.31.17

PLATINUM
AbbVie
American Brain Tumor Association
AstraZeneca
Brain Tumour Charity
Bristol-Myers Squibb
Cellnex Therapeutics
Genentech
National Brain Tumor Society
Novocure
Sontag Foundation

BENEFICTOR
Brainlab
Collaborative Ependymoma Research Network (CERN) Foundation
Orbus Therapeutics

CONTRIBUTOR
American Brain Tumor Association
Cancer Research UK
Celgene Corporation
Elekta
EndBrainCancer Initiative
Houston Methodist
Medtronic
Nativis Inc.
Northwest Biotherapeutics
Orbus Therapeutics
Tocagen

GENERAL EDUCATION
AstraZeneca
Celgene Corporation

IN MEMORY OF JAN ESENWEIN
Roger Abounader
Joe Adamo
Terri Armstrong
Naomi Berkowitz
Peter & Marla Phillips Burger
Howard Colman
Max & Barbara El Tawil
Richard Esenwein
J. Charles Haynes
Hope Hartman
Burt Feuerstein
Carol Kruchko
Lawrence Lamb
Barbara Langham
Joseph Lasky
Jason Levin
Dr. & Mrs. Victor Levin
Carolyn Loch
Tara Morrison
Kathy Oliver
Arie Perry
Essie Piwetz
Christine Quah
Allan Reece
Diana Simonetta
Michael Vogelbaum
Allen Waziri
Bachphuong Williams
Larry G. Wilson

INTERNATIONAL OUTREACH, LEVIN SOCIETY AND GENERAL DONATIONS
Anonymous
Children’s Brain Tumor Foundation
Naomi Berkowitz
Peter Clements
Diane Jaworski
Dr. & Mrs. Victor Levin
Wenyin Shi

EXHIBITORS
AbbVie
AbbVie Commercial
Ambry Genetics
American Brain Tumor Association
Arbor Pharmaceuticals
Hospital Team
Arbor Pharmaceuticals
Medical Affairs
Arbor Pharmaceuticals, LLC
AstraZeneca
Brain Tumour Charity
Brainlab
BriovaRX
Bristol-Myers Squibb
Caris Life Sciences
Cellnex Therapeutics
Collaborative Ependymoma Research Network (CERN) Foundation
City of Hope Laboratories
ContextMedia: Health
Elekta
Elsevier Inc.
End BrainCancer Initiative
Foundation Medicine
Genentech
Houston Methodist Hospital - Peak Center
Imaging Biometrics, LLC
Infuseon Therapeutics
Inovio Pharmaceuticals
Integrated Oncology
International Brain Tumour Alliance(IBTA)
IsoRay Medical
LabCorp
Li-Fraumeni Syndrome Association
MagForce AG
Make A Wish Foundation
Mayo Clinic
Med Learning Group
Medtronic
Monteris Medical
National Brain Tumor Society
Nativis Inc.
Nexstim
Nicki Leach Foundation
NICO Corporation
Northwest Biotherapeutics
Novartis Oncology
Novocure
Orbus Therapeutics, Inc.
Oxford University Press
PathGroup
Providence Health and Services
Reni'shaw PLC
RiboMed Biotechnologies, Inc.
Sigma Tau
Sontag Foundation
Synaptive Medical
Terra-Biological LLC.
Tocagen
UC Irvine Health
UCB, Inc.
University of Florida Health

CNS DRUG DISCOVERY MEETING SUPPORTERS
AbbVie
Agios
Bristol-Myers Squibb
Genentech
Pershing Square Sohm Cancer Research

PEDIATRIC CONFERENCE EXHIBITORS
A Kids’ Brain Tumor Cure Foundation
Foundation Medicine
International Symposium on Pediatric Neuro Oncology (ISPNO)
PedsDrugs.org
University of Florida Health

PEDIATRIC CONFERENCE SUPPORTERS
AbbVie
AstraZeneca
Bristol-Myers Squibb
Genentech
Pershing Square Sohm Cancer Research

(NBTS)
Pediatric Brain Tumor Foundation (PBTF)
MISSION
SNO fosters multidisciplinary neuro-oncology research and education to improve patient outcomes.

VISION
SNO is the pre-eminent multidisciplinary society involved in state-of-the-art neuro-oncology research, education, and patient care.
THE 2017 ANNUAL REPORT OF THE SOCIETY FOR NEURO-Oncology

Growth
Building a solid platform for GROWTH